)
Glenmark Pharmaceuticals has touched a new high of Rs 1,187 on the Bombay Stock Exchange (BSE) in early morning trades after the company said it has received final approval from the US drug regulator for drospirenone and ethinyl estradiol tablets.
“Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg, the generic version of Yaz tablets for Bayer Healthcare Pharmaceuticals Inc.” the company said in a release.
Glenmark plans to commence shipping of Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg immediately.
According to IMS Health sales data for the 12 months period ending June 2015, the Yaz market achieved annual sales of approximately $170.1 million, the company added.
At 09:32 AM, the stock was up 2% at Rs 1,182 on the BSE. A combined 155,233 shares changed hands on the counter on the BSE and NSE so far.
“Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg, the generic version of Yaz tablets for Bayer Healthcare Pharmaceuticals Inc.” the company said in a release.
Glenmark plans to commence shipping of Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg immediately.
According to IMS Health sales data for the 12 months period ending June 2015, the Yaz market achieved annual sales of approximately $170.1 million, the company added.
At 09:32 AM, the stock was up 2% at Rs 1,182 on the BSE. A combined 155,233 shares changed hands on the counter on the BSE and NSE so far.
